



OPPENHEIMER STRENGTHENS LIFE SCIENCES TEAM WITH NEW MANAGING DIRECTOR

New York, February 26, 2018 — Oppenheimer & Co. Inc. ("Oppenheimer") — a leading wealth manager and investment bank and a subsidiary of Oppenheimer Holdings (NYSE:OPY) — today announced Leland Gershell, M.D., Ph.D. joined the Firm as Managing Director and Senior Life Sciences Research Analyst. With extensive experience in the field, he is a welcome addition to Oppenheimer's expanding and distinguished Life Sciences research team.

Gershell joins from Capricor Therapeutics, which develops therapies for rare pediatric diseases, and previously served as CFO of Tonix Pharmaceuticals, a company developing small-molecule drug candidates for neuropsychiatric disorders. His achievements include raising over \$140 million across a variety of equity financing mechanisms and securing investment participation from leading Life Science institutions. Prior to his corporate roles, Gershell covered a variety of biotechnology and pharmaceutical companies as both a sell-side and buy-side analyst.

"This is a very dynamic time in the healthcare sector, with new therapies poised to revolutionize business models, as well as the continued focus on technology innovation using artificial intelligence and big data," said John Parks, Managing Director & Director of Equity Research at Oppenheimer. "Leland's experience, both financial and corporate, will reinforce significantly the domain expertise of the Life Sciences research team in this era of change and help to expand Oppenheimer's research offerings."

Healthcare and Life Sciences has historically been a strong focus for the Firm. Oppenheimer reaffirmed its commitment to Healthcare Investment Banking last year with a series of new hires.

-0-

Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.